Literature DB >> 26727519

Worldwide Prevalence of Fetal Alcohol Spectrum Disorders: A Systematic Literature Review Including Meta-Analysis.

Sylvia Roozen1,2, Gjalt-Jorn Y Peters2,3, Gerjo Kok1,2, David Townend1,4, Jan Nijhuis1,5, Leopold Curfs1,6.   

Abstract

BACKGROUND: Although fetal alcohol spectrum disorders (FASD) affect communities worldwide, little is known about its prevalence. The objective of this study was to provide an overview of the global FASD prevalence.
METHODS: We performed a search in multiple electronic bibliographic databases up to August 2015, supplemented with the ascendancy and descendancy approach. Studies were considered when published in English, included human participants, and reported empirical data on prevalence or incidence estimates of FASD. Raw prevalence estimates were transformed using the Freeman-Tukey double arcsine transformation so that the data followed an approximately normal distribution. Once the pooled prevalence estimates, 95% confidence intervals and prediction intervals were calculated based on multiple meta-analyses with transformed proportions using random effects models, these estimates were transformed back to regular prevalence rates. Heterogeneity was tested using Cochran's Q and described using the I(2) statistic.
RESULTS: Among studies that estimated prevalence in general population samples, considerable differences in prevalence rates between countries were found and therefore separate meta-analyses for country were conducted. Particularly high-prevalence rates were observed in South Africa for fetal alcohol syndrome (55.42 per 1,000), for alcohol-related neurodevelopmental disorder (20.25 per 1,000), and FASD (113.22 per 1,000), For partial fetal alcohol syndrome high rates were found in Croatia (43.01 per 1,000), Italy (36.89 per 1,000), and South Africa (28.29 per 1,000). In the case of alcohol-related birth defects, a prevalence of 10.82 per 1,000 was found in Australia. However, studies into FASD exhibited substantial heterogeneity, which could only partly be explained by moderators, most notably geography and descent, in meta-regressions. In addition, the moderators were confounded, making conclusions as to each moderator's relevance tentative at best.
CONCLUSIONS: The worldwide pooled prevalence estimates are higher than assumed so far, but this was largely explained by geography and descent. Furthermore, prevalence studies varied considerably in terms of used methodology and methodological quality. The pooled estimates must therefore be interpreted with caution and for future research it is highly recommended to report methodology in a more comprehensive way. Finally, clear guidelines on assessing FASD prevalence are urgently needed, and a first step toward these guidelines is presented.
Copyright © 2016 by the Research Society on Alcoholism.

Entities:  

Keywords:  Epidemiology; Fetal Alcohol Spectrum Disorder(s); Meta-Analysis; Prevalence; Systematic Literature Review

Mesh:

Year:  2016        PMID: 26727519     DOI: 10.1111/acer.12939

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  87 in total

Review 1.  Sleep in Infants and Children with Prenatal Alcohol Exposure.

Authors:  Sarah M Inkelis; Jennifer D Thomas
Journal:  Alcohol Clin Exp Res       Date:  2018-05-31       Impact factor: 3.455

Review 2.  Docosahexaenoic Acid: Outlining the Therapeutic Nutrient Potential to Combat the Prenatal Alcohol-Induced Insults on Brain Development.

Authors:  Bradley A Feltham; Xavier L Louis; Michael N A Eskin; Miyoung Suh
Journal:  Adv Nutr       Date:  2020-05-01       Impact factor: 8.701

3.  Addressing the nexus of risk: Biobehavioral outcomes from a cluster randomized trial of the Women's Health CoOp Plus in Pretoria, South Africa.

Authors:  Wendee M Wechsberg; Courtney Peasant Bonner; William A Zule; Charlie van der Horst; Jacqueline Ndirangu; Felicia A Browne; Tracy L Kline; Brittni N Howard; Nathaniel F Rodman
Journal:  Drug Alcohol Depend       Date:  2018-12-03       Impact factor: 4.492

4.  Placental Morphology in Fetal Alcohol Spectrum Disorders.

Authors:  Marlene Tai; Anna Piskorski; Jennifer C W Kao; Lynn A Hess; Suzanne M de la Monte; Füsun Gündoğan
Journal:  Alcohol Alcohol       Date:  2017-03-09       Impact factor: 2.826

Review 5.  Zinc deficiency as a mediator of toxic effects of alcohol abuse.

Authors:  Anatoly V Skalny; Margarita G Skalnaya; Andrei R Grabeklis; Anastasia A Skalnaya; Alexey A Tinkov
Journal:  Eur J Nutr       Date:  2017-11-24       Impact factor: 5.614

6.  Children with Heavy Prenatal Alcohol Exposure Exhibit Atypical Gait Characteristics.

Authors:  Tenille C Taggart; Roger W Simmons; Jennifer D Thomas; Edward P Riley
Journal:  Alcohol Clin Exp Res       Date:  2017-08-21       Impact factor: 3.455

7.  The BAF (BRG1/BRM-Associated Factor) chromatin-remodeling complex exhibits ethanol sensitivity in fetal neural progenitor cells and regulates transcription at the miR-9-2 encoding gene locus.

Authors:  Sasha G Burrowes; Nihal A Salem; Alexander M Tseng; Sridevi Balaraman; Marisa R Pinson; Cadianna Garcia; Rajesh C Miranda
Journal:  Alcohol       Date:  2017-04-07       Impact factor: 2.405

8.  Postnatal choline supplementation selectively attenuates hippocampal microRNA alterations associated with developmental alcohol exposure.

Authors:  Sridevi Balaraman; Nirelia M Idrus; Rajesh C Miranda; Jennifer D Thomas
Journal:  Alcohol       Date:  2017-01-03       Impact factor: 2.405

9.  Disconnect between alcohol-induced alterations in chromatin structure and gene transcription in a mouse embryonic stem cell model of exposure.

Authors:  Kylee J Veazey; Haiqing Wang; Yudhishtar S Bedi; William M Skiles; Richard Cheng-An Chang; Michael C Golding
Journal:  Alcohol       Date:  2017-01-11       Impact factor: 2.405

10.  Prenatal alcohol use as a risk for attention-deficit/hyperactivity disorder.

Authors:  Daniel Pagnin; Maria Luiza Zamboni Grecco; Erikson Felipe Furtado
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-10-23       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.